Inflammation, metaflammation and immunometabolic disorders

By G. Hotamışlıgil. Nature, 2017

2,159 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/2287d5ada554a620f2fba72e84055450d6d4f159

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Physiology

Citations in the corpus

Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner (2019, background): “First, macrophages are critically involved in the progression of obesity and its metabolic complications (Hotamisligil, 2017).”
Interaction between microbiota and immunity in health and disease (2020, background): “In metabolically highly active organs such as the liver or adipose tissue, the crosstalk between immune cells and parenchymal cells plays a critical role in the pathogenesis of metabolic diseases.(178) Growing evidence shows that gut microbiome-derived metabolites can reach systemic circulation thro”
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms (2017, background): “A recent meta-analysis of studies with anti-TNF agents supports an overall protective effect of anti-TNF therapies on lifetime risk of diabetes as well as insulin sensitivity and obesity.(74) A recent large proof of concept trial of anti-inflammatory therapy in patients after myocardial infarction (”
Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids (2018, background): “This process allows for the continuity of the inflammatory reaction, which is associated with conditions, such as atherogenesis and insulin-action resistance [52,53].”
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications (2024, background): “55 A very high rate of MASLD is observed in obese individuals, further strengthening the pathophysiological link between obesity and MASLD.”
The Sleep-Immune Crosstalk in Health and Disease (2019, background): “(109, 244, 336, 485, 572), as well as immunodeficiency due to impaired DC, T, and B cell functions (80, 199, 422), which in turn can promote failure of tumor and pathogen defense (123, 426) (reviewed in Ref.”
Metabolic Instruction of Immunity (2017, positive): “…inflammation is a well-established major risk factor for a plethora of diseases including heart disease, diabetes, metabolic syndromes, and cancer (Hotamisligil, 2017; Park et al., 2010), but our understanding of how inflammation contributes to the pathogenesis of these complex diseases is murky.”
Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease (2019, background): “Low-grade inflammation in adipose tissue and liver is a common feature of obesity and metabolic syndrome (Franceschi et al., 2018; Hotamisligil, 2017; Mori et al., 2010; Odegaard and Chawla, 2013).”
Metabolic Inflammation and Insulin Resistance in Obesity (2020, background): “DOI: 10.1161/CIRCRESAHA.119.315896 May 22, 2020 1559 Anti-Inflammatory Thrombosis Outcomes Study) did not show long-term benefits in reducing HbA1c and reductions in incident T2DM.186 The potential of other therapies targeting the NLRP3 inflammasome pathway in treating T2DM remains to be assessed.”
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? (2018, background): “JOURNAL OF HEPATOLOGY morpho-functional changes, occurring in a variety of organ systems that are potentially involved in the development of T2DM.”